Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Imugene Limited ( (AU:IMU) ) just unveiled an announcement.
Imugene Limited has announced the dosing of the first patient in Australia for its Phase II Neo-POLEM clinical trial, which investigates the PD1-Vaxx vaccine’s potential to enhance treatment outcomes for a specific type of colorectal cancer. This trial, conducted in collaboration with Cancer Research UK and other partners, aims to assess the vaccine’s efficacy in reducing tumor size and improving survival rates, offering hope for patients with this challenging cancer subtype.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene Limited stock, see the AU:IMU Stock Forecast page.
More about Imugene Limited
Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative cancer immunotherapies. The company is engaged in creating treatments that harness the body’s immune system to target and eradicate cancer cells, with a market focus on improving outcomes for cancer patients.
Average Trading Volume: 18,659,399
Technical Sentiment Signal: Sell
Current Market Cap: A$82.14M
Learn more about IMU stock on TipRanks’ Stock Analysis page.